Overview

Clinical Trial of High Dose CoQ10 in ALS

Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy and preferred dose of CoQ10 in individuals with ALS for a possible future phase III study.
Phase:
Phase 2
Details
Lead Sponsor:
Columbia University
Collaborator:
National Institute of Neurological Disorders and Stroke (NINDS)
Treatments:
Antioxidants
Coenzyme Q10
Ubiquinone